Patient characteristics are consistent with other DLB studies -PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, ...

Fractyl Health (GUTS) presented the poster, “Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease,” on ...

WALTHAM, Mass. and BOULDER, Colo., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

The poster to be presented at ASH 2024 builds on the data presented earlier this year at the European Haematology Association 2024 Congress and provides further preclinical in vivo proof-of-mechanism ...

CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, today announced topline int ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...

CINCINNATI--(BUSINESS WIRE)--CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, will present two posters at ObesityWeek ...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody ...

REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 ...

Hanging on his wall, the poster was a collage in which Macrus ... Marcus dropped out of the college basketball team, focusing on his studies and business. Marcus Jordan played both high school ...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders ...

A poster containing additional data was also shared at this event, a copy of which can be found on Absci's website. Absci continues to advance ABS-101 through IND-enabling studies ... our expectations ...